R&D capability：

Peptide drugs have similar characteristics to protein drugs. Compared to small molecule drugs, the process technology is complex. Although the small-scale trials are relatively easy, the scale-up effect is significant, and the technical barriers to large-scale production are high. The quality research of starting materials, intermediates, and finished products involves a wide range of content, requires a large amount of work, and is difficult to develop analytical methods. The Sinodo Pharmaceutical team has gathered technical elites in various fields such as process, analysis, registration, GMP production, and enterprise management. They are skilled in the entire process of polypeptide products from laboratory to industrialization, and have the ability and experience to solve various difficult problems in the development process of polypeptide drugs. The R&D ability and product quality have been recognized by peers at home and abroad.